Essential Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Essential Partners's REGN Position: Q2 2026 in Review
Essential Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 3% in Q2 2026, selling an estimated $15K and leaving 713 shares worth $445K. The position accounts for 0.2% of the portfolio, ranked #89.
Essential Partners first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.24M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Essential Partners held 713 shares of Regeneron Pharmaceuticals worth $445K as of Q2 2026.
- Essential Partners sold 22 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $15K.
- Regeneron Pharmaceuticals made up 0.2% of Essential Partners's portfolio in Q2 2026, its #89 holding.
- Essential Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
- Essential Partners's Regeneron Pharmaceuticals position peaked at $1.24M in Q4 2025.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.